Emily K. Fay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emily K. Fay has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Daniel Herzig
Department of Gastrointestinal and General Surgery, Oregon Health and Science University, Portland, OR
1 shared publication- Julie Nicole Graff
Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
1 shared publication Kaveh Sharzehi
Department of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, OR
1 shared publicationStephen E. Spurgeon
Department of Hematology and Oncology, Oregon Health and Science University, Portland, OR
1 shared publication
Latest Publications
- 1 August 2020
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (8) , e485-e487
The First Report of Endoscopic Ultrasound-guided Intralesional Rituximab in a Patient With Mantle Cell Lymphoma Presenting With Isolated Colorectal Involvement
- 1 August 2020
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (8) , e485-e487
The First Report of Endoscopic Ultrasound-guided Intralesional Rituximab in a Patient With Mantle Cell Lymphoma Presenting With Isolated Colorectal Involvement
- Open Access
Immunotherapy in Prostate Cancer
Immunotherapy encompasses a wide range of therapies to engage the immune system to target malignancies. In recent years, immunotherapy has made a major impact on treatment of metastatic cancer and has altered standard of care for many tumor types. However, predicting and understanding responses across tumor types has been challenging. While some metastatic cancers have shown dramatic responses to immunotherapy, such as melanoma, lung cancer, and renal cell carcinoma, prostate cancer has generally failed to show a significant response. However, small series of prostate cancer patients have shown impressive responses to cellular and immunotherapy. This review summarizes the current data for immunotherapy’s use in prostate cancer, as well as how currently available data might help predict patient responses to immunotherapy. Specifically, we will review vaccine-based therapies, immune checkpoint inhibitors, and future directions that are actively being explored.
Open AccessImmunotherapy in Prostate Cancer
Immunotherapy encompasses a wide range of therapies to engage the immune system to target malignancies. In recent years, immunotherapy has made a major impact on treatment of metastatic cancer and has altered standard of care for many tumor types. However, predicting and understanding responses across tumor types has been challenging. While some metastatic cancers have shown dramatic responses to immunotherapy, such as melanoma, lung cancer, and renal cell carcinoma, prostate cancer has generally failed to show a significant response. However, small series of prostate cancer patients have shown impressive responses to cellular and immunotherapy. This review summarizes the current data for immunotherapy’s use in prostate cancer, as well as how currently available data might help predict patient responses to immunotherapy. Specifically, we will review vaccine-based therapies, immune checkpoint inhibitors, and future directions that are actively being explored.